Elekta ended FY22 on a healthy note, with Q4 results exceeding street expectations. Sales growth was witnessed in both segments. Importantly, order intake growth was maintained and the dividend was also increased by c.9%. Although profitability was visibly restrained and management expects challenges to remain in Q1, the firm’s innovation prowess, partnership initiatives and promising long-term oncology market dynamics support Elekta’s investment case and, hence, the firm emerges as one of our p ....
